Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Gene Therapy Clinical Development

• Publication date

  2016-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/humc.2016.056PMID 27470285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia : The Findings , the Debate , and the Therapeutic Implications

  2016cited by this paper
• Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

  2014cited by this paper
• Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

  2014cited by this paper
• GTP cyclohydrolase regulation: implications for brain development and function.

  2013cited by this paper
• Modulation of striatal projection systems by dopamine.

  2011cited by this paper
• A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

  2010cited by this paper
• Development of inducible EIAV-based lentiviral vector packaging and producer cell lines

  2009cited by this paper
• Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

  2009cited by this paper
• Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia

  2009cited by this paper
• Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

  2008cited by this paper
• Direct Binding of GTP Cyclohydrolase and Tyrosine Hydroxylase

  2008cited by this paper
• Factors that influence VSV‐G pseudotyping and transduction efficiency of lentiviral vectors—in vitro and in vivo implications

  2007cited by this paper
• Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

  2006cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference1

  2002cited by this paper
• Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes

  2002cited by this paper
• Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease.

  2002cited by this paper
• GTP cyclohydrolase I mRNA: novel splice variants in the slime mould Physarum polycephalum and in human monocytes (THP-1) indicate conservation of mRNA processing.

  2001cited by this paper
• Triple Transduction with Adeno-Associated Virus Vectors Expressing Tyrosine Hydroxylase, Aromatic-L-Amino-Acid Decarboxylase, and GTP Cyclohydrolase I for Gene Therapy of Parkinson's Disease

  2000cited by this paper
• Dopamine agonists in the treatment of Parkinson s disease past, present and future.

  2000cited by this paper
• IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector.

  2000cited by this paper
• Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease.

  1999cited by this paper
• Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic L-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors

  1998cited by this paper
• In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.

  1998cited by this paper
• Rat GTP cyclohydrolase I is a homodecameric protein complex containing high-affinity calcium-binding sites.

  1998cited by this paper
• [Problems of long-term levodopa therapy in Parkinson's disease].

  1997cited by this paper
• Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases

  1997cited by this paper
• Elucidation of crystal packing by X-ray diffraction and freeze-etching electron microscopy. Studies on GTP cyclohydrolase I of Escherichia coli.

  1995cited by this paper
• Recent advances in pharmacological therapy of Parkinson's disease.

  1993cited by this paper

• Recent developments in gene therapy for Parkinson's disease.

  2025cites this paper
• Disease-specific interventions: The use of cell and gene therapies for Parkinson disease.

  2024cites this paper
• Oligodendrocytes, the Forgotten Target of Gene Therapy

  2024cites this paper
• Gene therapy for CNS disorders: modalities, delivery and translational challenges

  2024cites this paper
• A review of the advances, insights, and prospects of gene therapy for Alzheimer's disease: A novel target for therapeutic medicine.

  2024cites this paper
• Viral vectors for gene delivery to the central nervous system.

  2024cites this paper
• Clinical gene therapy development for the central nervous system: Candidates and challenges for AAVs.

  2023cites this paper
• Genetically engineered mesenchymal stem cells with dopamine synthesis for Parkinson’s disease in animal models

  2022cites this paper
• Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease

  2021cites this paper
• Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease.

  2021cites this paper
• Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

  2021cites this paper
• Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry

  2020cites this paper
• Development of new self-assembled cationic amino liposomes for efficient gene delivery.

  2020cites this paper
• Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry.

  2020cites this paper
• Extracellular Vesicles as Nanotherapeutics for Parkinson’s Disease

  2020cites this paper
• Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?

  2020cites this paper
• Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis

  2019cites this paper
• RNA Viruses as Tools in Gene Therapy and Vaccine Development

  2019cites this paper
• Human tyrosine hydroxylase in Parkinson’s disease and in related disorders

  2018cites this paper
• Repairing the Brain: Gene Therapy

  2018cites this paper
• Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

  2018cites this paper
• Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

  2018influential citation
• microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches

  2017cites this paper
• Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study

  2017cites this paper
• Gene Therapy in the Nervous System: Failures and Successes.

  2017cites this paper